Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Jan 7, 2016	Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer Introduction of blood-based assay to detect androgen receptor expression builds on leading position in detecting and monitoring cancer through liquid biopsy	View HTML Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer 43.5 KB
Toggle Summary Dec 22, 2015	Biocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund SAN DIEGO , Dec. 22, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC) (" Biocept " or the "Company"), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock	View HTML Biocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund 45.9 KB
Toggle Summary Dec 14, 2015	Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis Companies to take next step following successful completion of feasibility studies PHILADELPHIA & REHOVOT, Israel & SAN DIEGO --(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.	View HTML Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis 27.9 KB
Toggle Summary Dec 7, 2015	Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for Estrogen Receptor Gene Monitoring for ESR1 mutations in breast cancer patients could play a key role in therapeutic decision making	View HTML Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for Estrogen Receptor Gene 42.5 KB
Toggle Summary Nov 30, 2015	Biocept Gains Patent Protection in Hong Kong and Japan Allowances extend Biocept's OncoCEE rare cell analysis microchannel patent coverage	View HTML Biocept Gains Patent Protection in Hong Kong and Japan 50.4 KB
Toggle Summary Nov 25, 2015	Biocept to Present at LD Micro Main Event SAN DIEGO , Nov. 25, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, announces that President and CEO Michael Nall is	View HTML Biocept to Present at LD Micro Main Event 46.4 KB
Toggle Summary Nov 23, 2015	Biocept Secures Agreements with Preferred Provider Organizations Fortified Provider Network and Three Rivers Provider Network Increases patient in-network coverage to approximately 133 million PPO consumers	View HTML Biocept Secures Agreements with Preferred Provider Organizations Fortified Provider Network and Three Rivers Provider Network 51 KB
Toggle Summary Nov 16, 2015	Biocept to Present Data Demonstrating a High Correlation of Biomarker Detection from its Liquid Biopsy Assays and Tissue Samples at the SelectBIO Biofluid Biopsies & High-Value Diagnostics 2015 Meeting SAN DIEGO , Nov. 16, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, today announced the presentation of recent analytical	View HTML Biocept to Present Data Demonstrating a High Correlation of Biomarker Detection from its Liquid Biopsy Assays and Tissue Samples at the SelectBIO Biofluid Biopsies & High-Value Diagnostics 2015 Meeting 52.4 KB
Toggle Summary Nov 11, 2015	Biocept Expands Patent Protection in Europe European patent covers the use of antibodies in the capture and detection of rare cells from biological fluids used in the company's liquid biopsy, or blood-based, molecular diagnostic assays	View HTML Biocept Expands Patent Protection in Europe 50.3 KB
Toggle Summary Nov 5, 2015	Biocept Reports Third Quarter 2015 Financial Results Expands leadership position by launching additional tumor-associated blood-based biomarker assaysDrives 43% sequential growth in commercial assaysConference call begins at 4:30 p.m. Eastern time today	View HTML Biocept Reports Third Quarter 2015 Financial Results 69.4 KB

Investor Relations

Press Releases

Contact Biocept, Inc.